Kymera Investor Day Presentation Deck
●
●
KT-413 is a Potent Degrader of IRAK4 and IMID Substrates
with Potent Activity in MYD88MT Cell lines
KT-413 selectively degrades
both IRAK4 and IMiD
substrates which leads to a
profound antitumor effect in
vitro and in vivo
KT-413 is more active in
MYD88MT DLBCL cells than
the clinically active IMiD, CC-
220, and IRAK4-selective
degrader, KTX-545
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
Fraction of DMSO
IRAK4 DC50
Ikaros DC50 = 2 nM
Aiolos DC50 = 2 nM
1.00
0.75
0.50
0.25
0.00
KT-413
=
T
-2
6 nM
OCI-Ly10 (MYD88L265P)
KT-413
CC220
KTX-545
OCI-Ly-10
(MYD88MT DLBCL)
EC50 = 1 nM
-1
Log [compound], μM
1
KYMERA R&D DAY - December 16th, 2021
CTG (% Growth Inhibition)
Fraction of DMSO
100
80
60
40
O
1.00
0.75
0.50
0.25
0.00
0.1
H
HKH
-3
1
HH
SUDHL2 (MYD885222R)
Concentration (nM)
10
HOW
KT-413
CC220
KTX-545
HH
HH
K
-2
-1
0
Log [compound], µM
IRAK4
Ikaros
Aiolos
CTG
100
1
▶
100
-80
-60
40
-20
-0
Degradation (% Control)
PAGE 52View entire presentation